MEDP — Medpace Holdings Share Price
0.000.00%
Last trade - 00:00- $8.96bn
- $8.29bn
- $2.11bn
- 98
- 37
- 62
- 72
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 23.44 | ||
| PEG Ratio (f) | 24.88 | ||
| EPS Growth (f) | 0.95% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 10.85 | ||
| Price to Tang. Book | 69.54 | ||
| Price to Free Cashflow | 15.65 | ||
| Price to Sales | 4.25 | ||
| EV to EBITDA | 17.4 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 44.85% | ||
| Return on Equity | 58.41% | ||
| Operating Margin | 21.19% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 925.92 | 1,142.38 | 1,460 | 1,885.84 | 2,109.05 | 2,149.26 | 2,336.71 | 19.62% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +44.18 | +25.2 | +51.35 | +21.88 | +42.3 | -2.86 | +10.16 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Medpace Holdings, Inc. is a scientifically driven, global, full-service clinical contract research organization (CRO) providing phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Company’s operations are principally based in North America, Europe, and Asia.
Directors
- August Troendle CHM (64)
- Jesse Geiger PRE (47)
- Kevin Brady CFO
- Susan Burwig EVP (58)
- Stephen Ewald GCN (51)
- Fred Davenport LED (69)
- Brian Carley IND (67)
- Ashley Keating IND (39)
- Thomas King IND (63)
- Robert Kraft IND (50)
- Cornelius McCarthy IND (61)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- February 18th, 2014
- Public Since
- August 11th, 2016
- No. of Shareholders
- 8
- No. of Employees
- 5,900
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 30,228,414
- Address
- 5375 Medpace Way, CINCINNATI, 45227-1543
- Web
- https://investor.medpace.com/
- Phone
- +1 5135799911
- Auditors
- Deloitte & Touche LLP
Upcoming Events for MEDP
Medpace Holdings Inc Annual Shareholders Meeting
Medpace Holdings Inc Annual Shareholders Meeting
Q2 2025 Medpace Holdings Inc Earnings Release
Q3 2025 Medpace Holdings Inc Earnings Release
Similar to MEDP
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
Aardvark Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
FAQ
What is the Medpace Holdings share price?
As of Today at 21:58 UTC, shares in Medpace Holdings are trading at $296.28. This share price information is delayed by 15 minutes.
How has the Medpace Holdings share price performed this year?
Shares in Medpace Holdings last closed at $296.28 and the price had moved by -22.53% over the past 365 days. In terms of relative price strength the Medpace Holdings share price has underperformed the S&P500 Index by -27.16% over the past year.
What are the analyst and broker recommendations for Medpace Holdings?
The overall consensus recommendation for Medpace Holdings is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Medpace Holdings dividend yield?
Medpace Holdings does not currently pay a dividend.
Does Medpace Holdings pay a dividend?
Medpace Holdings does not currently pay a dividend.
When does Medpace Holdings next pay dividends?
Medpace Holdings does not currently pay a dividend.
How do I buy Medpace Holdings shares?
To buy shares in Medpace Holdings you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Medpace Holdings?
As of the previous close price of $296.28, shares in Medpace Holdings had a market capitalisation of $8.96bn.
Where are Medpace Holdings shares listed?
Here are the trading details for Medpace Holdings:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: MEDP
What kind of share is Medpace Holdings?
Based on an overall assessment of its quality, value and momentum Medpace Holdings is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Medpace Holdings share price forecast for 2025?
The analyst consensus target price for shares in Medpace Holdings is $336.33. That is 13.52% above the last closing price of $296.28.
Analysts covering Medpace Holdings currently have a consensus Earnings Per Share (EPS) forecast of $12.27 for the next financial year.
Find out moreWhat is the trend in the Medpace Holdings share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Medpace Holdings. Over the past six months, its share price has underperformed the S&P500 Index by -7.88%.
As of the last closing price of $296.28, shares in Medpace Holdings were trading -14.92% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Medpace Holdings PE Ratio?
The Medpace Holdings PE ratio based on its reported earnings over the past 12 months is 23.44. The shares last closed at $296.28.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Medpace Holdings?
Medpace Holdings' management team is headed by:
- August Troendle - CHM
- Jesse Geiger - PRE
- Kevin Brady - CFO
- Susan Burwig - EVP
- Stephen Ewald - GCN
- Fred Davenport - LED
- Brian Carley - IND
- Ashley Keating - IND
- Thomas King - IND
- Robert Kraft - IND
- Cornelius McCarthy - IND